(Q44696938)

5 December 2017

title

The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma (English)

1 reference

5 December 2017

Bronwen E Shaw

1

1 reference

5 December 2017

Karl Peggs

2

1 reference

5 December 2017

Jennifer M Bird

3

1 reference

5 December 2017

Jamie Cavenagh

4

1 reference

5 December 2017

A Hunter

5

1 reference

5 December 2017

J Alejandro Madrigal

6

1 reference

5 December 2017

Nigel H Russell

7

1 reference

5 December 2017

Bhawna Sirohi

8

1 reference

5 December 2017

Keiren Towlson

9

1 reference

5 December 2017

Catherine D Williams

10

1 reference

5 December 2017

David I Marks

11

1 reference

5 December 2017

Clinical Trials Committee of the British Society of Blood and Marrow Transplantation

12

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

British Journal of Haematology

5 December 2017

published in

1 reference

5 December 2017

volume

123

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

886-895

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04714.X

10.1046/J.1365-2141.2003.04714.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference